Collection of Alveolar Soft Part Sarcoma and Blood Specimens for Research
| Status: | Completed |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 4 - Any |
| Updated: | 4/21/2016 |
| Start Date: | April 2005 |
| End Date: | April 2012 |
Procurement of Blood and Tissue From Patients With Primary and Metastatic Alveolar Soft Part Sarcoma and Blood From Healthy Controls for In Vitro and In Vivo Model Development
Background:
Alveolar soft part sarcoma (ASPS) is a rare tumor.
ASPS is resistant to chemotherapy and radiation.
ASPS is characterized by slow growth.
Currently no in vitro or in vivo models of ASPS exist for use in experimental therapeutic
studies or biological investigations.
Primary Objectives:
Acquisition of blood and tissue from patients with ASPS.
Acquisition of blood from healthy controls for comparison with blood from patients with
ASPS. These control samples will be obtained from study NCI at Frederick Protocol
OH99-C-N046.
Eligibility:
Subjects of any age with a diagnosis of primary or metastatic alveolar soft part sarcoma who
are undergoing medically indicated surgery for their disease.
Design:
Patients with Alveolar Soft Part Sarcoma (ASPS) will be eligible for this study. Biopsy
tissue will be obtained as an additional sample at the time of a medically indicated
procedure. Blood sample may be collected at initial visit and follow-up visits. Specific
risks will be described in a separate consent to be obtained at the time of the biopsy.
Tumor samples and blood samples will be processed and/or stored for use in research efforts
in the laboratory of Dr. David Vistica, National Cancer Institute, Frederick, MD.
Additionally, blood samples will be obtained from healthy volunteers for comparison to
patients with ASPS. These control samples will be obtained from the National Cancer
Institute at Frederick Protocol OH99-C-N046.
Alveolar soft part sarcoma (ASPS) is a rare tumor.
ASPS is resistant to chemotherapy and radiation.
ASPS is characterized by slow growth.
Currently no in vitro or in vivo models of ASPS exist for use in experimental therapeutic
studies or biological investigations.
Primary Objectives:
Acquisition of blood and tissue from patients with ASPS.
Acquisition of blood from healthy controls for comparison with blood from patients with
ASPS. These control samples will be obtained from study NCI at Frederick Protocol
OH99-C-N046.
Eligibility:
Subjects of any age with a diagnosis of primary or metastatic alveolar soft part sarcoma who
are undergoing medically indicated surgery for their disease.
Design:
Patients with Alveolar Soft Part Sarcoma (ASPS) will be eligible for this study. Biopsy
tissue will be obtained as an additional sample at the time of a medically indicated
procedure. Blood sample may be collected at initial visit and follow-up visits. Specific
risks will be described in a separate consent to be obtained at the time of the biopsy.
Tumor samples and blood samples will be processed and/or stored for use in research efforts
in the laboratory of Dr. David Vistica, National Cancer Institute, Frederick, MD.
Additionally, blood samples will be obtained from healthy volunteers for comparison to
patients with ASPS. These control samples will be obtained from the National Cancer
Institute at Frederick Protocol OH99-C-N046.
Background:
Alveolar soft part sarcoma (ASPS) is a rare tumor.
ASPS is resistant to chemotherapy and radiation.
ASPS is characterized by slow growth.
Currently no in vitro or in vivo models of ASPS exist for use in experimental therapeutic
studies or biological investigations were generated under this protocol.
Additional models are needed to represent the heterogeneity of this disease.
Primary Objectives:
Acquisition of blood and tissue from patients with ASPS.
Acquisition of blood from healthy controls for comparison with blood from patients with
ASPS. These control samples will be obtained from study NCI at Frederick Protocol
OH99-C-N046.
Eligibility:
Subjects of any age with a diagnosis of primary or metastatic alveolar soft part sarcoma who
are undergoing medically indicated surgery for their disease.
Design:
Patients with Alveolar Soft Part Sarcoma (ASPS) will be eligible for this study. Biopsy
tissue will be obtained as an additional sample at the time of a medically indicated
procedure. Blood sample may be collected at initial visit and follow-up visits. Specific
risks will be described in a separate consent to be obtained at the time of the biopsy.
Tumor samples and blood samples will be processed and/or stored for use in research efforts
in the laboratory of Dr. Robert Shoemaker, National Cancer Institute, Frederick, MD.
Additionally, blood samples will be obtained from healthy volunteers for comparison to
patients with ASPS. These control samples will be obtained from the National Cancer
Institute at Frederick Protocol OH99-C-N046.
Alveolar soft part sarcoma (ASPS) is a rare tumor.
ASPS is resistant to chemotherapy and radiation.
ASPS is characterized by slow growth.
Currently no in vitro or in vivo models of ASPS exist for use in experimental therapeutic
studies or biological investigations were generated under this protocol.
Additional models are needed to represent the heterogeneity of this disease.
Primary Objectives:
Acquisition of blood and tissue from patients with ASPS.
Acquisition of blood from healthy controls for comparison with blood from patients with
ASPS. These control samples will be obtained from study NCI at Frederick Protocol
OH99-C-N046.
Eligibility:
Subjects of any age with a diagnosis of primary or metastatic alveolar soft part sarcoma who
are undergoing medically indicated surgery for their disease.
Design:
Patients with Alveolar Soft Part Sarcoma (ASPS) will be eligible for this study. Biopsy
tissue will be obtained as an additional sample at the time of a medically indicated
procedure. Blood sample may be collected at initial visit and follow-up visits. Specific
risks will be described in a separate consent to be obtained at the time of the biopsy.
Tumor samples and blood samples will be processed and/or stored for use in research efforts
in the laboratory of Dr. Robert Shoemaker, National Cancer Institute, Frederick, MD.
Additionally, blood samples will be obtained from healthy volunteers for comparison to
patients with ASPS. These control samples will be obtained from the National Cancer
Institute at Frederick Protocol OH99-C-N046.
- INCLUSION CRITERIA:
Subjects of any age with a diagnosis of primary or metastatic alveolar soft part sarcoma
who are undergoing medically indicated surgery for their disease.
EXCLUSION CRITERIA:
We found this trial at
1
site
9609 Medical Center Drive
Bethesda, Maryland 20892
Bethesda, Maryland 20892
1-800-422-6237
National Cancer Institute , 9000 Rockville Pike The National Cancer Institute (NCI) is part of...
Click here to add this to my saved trials
